期刊文献+

系统性红斑狼疮患者血清泌乳素水平的前瞻性研究 被引量:3

Prospective study on serum levels of prolactin in patients of systemic lupus erythematosus
在线阅读 下载PDF
导出
摘要 目的 探讨系统性红斑狼疮(SLE)患者血清泌乳素(PRL)水平与SLE活动期的关系。方法 应用时间分辨免疫发光试验(TrFIA)测定113例SLE患者和30名正常人血清PRL水平,ELISA测定血清IL-2R的浓度,用SLEDAI评估了113例SLE患者的病情活动性以及Logistic多元回归研究临床表现、免疫学指标与高PRL血症的关系。结果63例SLE活动期患者血清PRL水平(14±7)μg/L显著高于50例静止期患者(12±8)μg/L和30名正常对照组(7±6)μg/L;74.9%的活动期患者血清PRL水平在9-51.2μg/L;113例SLE患者血清PRL水平与dsDNA抗体、SLEDAI呈线性正相关 ;Logistic多元回归研究发现蛋白尿、低C3和高dsDNA抗体滴度与高PRL血症相关。结论SLE患者血清PRL轻度升高与SLE的病情活动性相关。 Objective To study the association of serum prolactin (PRL) levels with the disease activity in the patients of systemic lupus erythematosus (SLE). Methods The author measured serum PRL levels with time-resolved fluoroimmunoassay (TrFIA) in 113 patients of SLE and in 30 gender-aged-paired controls, estimated SLEDAI, investigated the association of clinic, immunologic index and high anti-dsDNA antibodies titers with hyperprolactinemia by logistic regression in 113 patients of SLE. Results The serum PRL levels of 63 active patients are higher than that of 50 inactive patients and that of 30 control subjects. The serum PRL levels are ranging 9-51.2μg/L in 79.3 percent active patients. 50% patients in active group are in 15 51 .2μg/ L. It is also found that PRL level was linearly positively related to anti-double strand DNA antibodies titers. The concentration of interleukin 2 receptors in hyperprolactinemia group is higher than that of normal group. Logistic regression showed that proteinuria, low levels of complement 3 and high anti-dsDNA antibodies titers correlate with hyperprolactinemia. Conclusion The milidly elevated serum levels of PRL are associated with activity of SLE.
出处 《中国药物与临床》 CAS 2001年第1期7-9,共3页 Chinese Remedies & Clinics
基金 国家自然科学基金资助项目(39770688)
关键词 PRL 患者 SLEDAI 血清泌乳素 系统性红斑狼疮 活动期 病情活动 DNA 水平 人血清 Lupus erythematosus, systemic Prolactin Prospective study
  • 相关文献

参考文献10

  • 1Bombardier C,Gladman DD,Urowitz MB,et al.Derivation of the SLEDAI:a disease activity index for lupus patients.Arthritis Rheum,1992,35:630-640.
  • 2Jin L,Qian X,Kulig E,et al.Prolactin receptors messenger ribonucleic acid in normal and neoplastic human pituitary tissues.J Clin Endocrinol Metab,1997,82(3):963-968.
  • 3Jara LJ,Gomez-Sanchezc C,Siverira LH,et al.Hyperprolactinemia in systemic lupus erythematosus:associaton with disease activity.Am J Med Sci,1992,303:222-226.
  • 4Gutierrez MA,Molina JF,Jara LJ,et al.Prolactin-induced immunoglobins and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals.Int Arch Allergy Immunol,1996,109:229-235.
  • 5Larrea F,Martinez-Castillo A,Cabrera V,et al.A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus.J Clin Endocrinol Metab,1997,82(11):3664-3669.
  • 6Allen SH,Sharp CC,Wang G,et al.Prolactin levels and antinuclear antibody profile in woman tested for connective tissue disease.Lupus,1996,5:30-37.
  • 7Miranda JM,Prieto RE,Paniagua R,et al.Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis.Lupus,1998,7:387-391.
  • 8李峰,冯树芳,徐金华,黄岚,邓守贞.系统性红斑狼疮患者血清生长激素和泌乳素动态变化的研究[J].中华皮肤科杂志,2000,33(4):261-263. 被引量:12
  • 9李峰,冯树芳,徐金华,黄岚,邓守真.SLE和皮肌炎患者下丘-垂体-甲状腺轴的研究[J].临床皮肤科杂志,2000,29(2):73-75. 被引量:5
  • 10Brema P,Hajeer A,Ollier B,et al.Allelic markers close to prolactin are associated with HLA-DRB1 susceptibility alleles among women with rheumatoid arthritis and systemic lupus erythematosus.Arthritis Rheum,1997,40:1383-1386.

二级参考文献6

共引文献13

同被引文献45

  • 1卢文,董家麟.SLE患者血清性激素含量变化及其临床意义[J].上海免疫学杂志,1995,15(6):361-362. 被引量:7
  • 2刘志民,顾明君,石勇铨,谢侃远.系统性红斑狼疮患者性激素及性激素受体的改变及意义[J].标记免疫分析与临床,1996,3(1):1-3. 被引量:8
  • 3Verthelyis D. Sex hormones as immunomodulators in health and disease. Intern Immunopharm,2001,(6): 983-993.
  • 4Suenaga R, Mitamura K, Evans MJ, et al. Binding affinity and quantity of estrogen receptor in peripheral blood monocytes of patients with systemic lupus erythematosus. Lupus, 1996,5(3): 227-231.
  • 5Rider V, Abdou NI. Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Internat Immunopharm, 2001,1(6): 1009-1024.
  • 6Rider V, Jones SR, Evans M, et al. Molecular mechanism involved in the estrogen-dependent regulation of calineurin in system lupus erythematosus T cells. Clin Immunol, 2000,95(2): 124-134.
  • 7Folomeev M, Dougados M, Beaune J, et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus, 1992,1(3):191-195.
  • 8Meier CR, Sturkenboom MC, Cohen AS, et al. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheum, 1998,25(8): 1515-1519.
  • 9Petri M. Postmenopausal estrogen replacement therapy and risk of developing systemic lupus erythematosus or discoid lupus. J Rheum, 1999,26(3): 752.
  • 10Dhaher YY, Greenstein B, Fougerolles NE, et al. Strain differences in binding properties of estrogen receptors in immature and adult BALB/c and MRL/MP-lpr/lprmice, a model of systemic lupus erythematosus. Int J Immunopharm, 2000,22(3): 247-254.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部